[home]
[thesaurus]
Click Here to return To Results
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
See this aricle in Pubmed
Article Abstract
Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab.
Related Tags
(click to filter results - removes previous filter)
adverse drug reaction
B cell lymphocytes
carcinoma
carcinoma of breast
complications
efficacy
herpes virus infection
infection
MRI,abnormal
multiple sclerosis
multiple sclerosis,chronic progressive
multiple sclerosis,prophylaxsis
multiple sclerosis,treatment of
ocrelizumab
placebo
safety
treatment of neurologic disorder
viral infection,reactivation
Click Here to return To Results